Kyverna Therapeutics Bolsters Board with Biotech Veterans Ahead of Commercial Push
Event summary
- Kyverna Therapeutics appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors on February 24, 2026.
- Sravan Emany, CFO of Beam Therapeutics, assumes the role of Audit Committee Chair, replacing Dan Spiegelman.
- Andrew Miller, former President of R&D at Karuna Therapeutics, brings clinical development and product approval expertise.
- Emany's background includes leadership roles in rare disease cell and gene companies, and investment banking.
- Miller was named to Time Magazine’s 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025.
The big picture
Kyverna's board refresh aligns with its transition from clinical-stage to commercialization, a critical phase for autoimmune cell therapy players. The appointments underscore the company's focus on scaling its lead candidate, miv-cel, while leveraging the new directors' proven expertise in navigating regulatory and market hurdles. The move also signals a governance shift towards financial and operational discipline as Kyverna prepares for potential high-stakes partnerships or acquisitions.
What we're watching
- Commercialization Timing
- How Emany's rare disease commercialization experience will accelerate Kyverna's push towards market readiness.
- Clinical Development
- Whether Miller's track record in product approvals can streamline Kyverna's ongoing registrational trials.
- Strategic Pivots
- The pace at which the new board members drive shifts in Kyverna's neuroimmunology franchise strategy.